Countries Request a quote
Semax / Selank Blend — Alphagenics vial
Cognitive and Neurological Health

Semax / Selank Blend

Semax + Selank

Combination of neuroactive heptapeptides

Components2
Total10mg
Available presentations
Spray format
Certificate of analysis (COA)
10mg
Request a quote Quick guide Research protocol Spray protocol View evidence Reconstitution calculator Physician login

About Semax / Selank Blend

This presentation combines two synthetic heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.

Both share the C-terminal stabilizing sequence Pro-Gly-Pro. Semax, derived from ACTH (4-7), has been studied for its relationship with BDNF and cognitive function; Selank, derived from tuftsin, for its anxiolytic activity and its possible action on the GABAergic system. The combination brings both lines of research together in a single vial.

Quick guide · 5 key points

Semax and Selank: two peptides, one vial

This blend combines two synthetic heptapeptides with the same stabilizing tail: Semax, studied for BDNF, and Selank, studied for anxiety. Here are five things the research shows.

View research protocolProtocol (PDF) Open guide (PDF) Download guide
  1. 1

    Two peptides with the same Pro-Gly-Pro tail

    Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH (4-10) analogue and Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a tuftsin analogue. Both end in Pro-Gly-Pro, and they are combined because they have been studied along two different lines: cognitive function and anxiety.1,2

    SemaxStudied for BDNF, learning and recovery after stroke.
    SelankStudied for anti-anxiety activity and its action on the GABA system.
    Pro-Gly-ProThe end sequence both peptides share
  2. 2

    Semax: BDNF in rats and stroke patients

    In rats, a single dose of Semax was associated with a 1.4-fold rise in BDNF in the hippocampus. In a study of 110 patients after ischemic stroke, it was associated with higher plasma BDNF and faster functional recovery.3,4

    1.4×more BDNF in rat hippocampus after one dose
  3. 3

    Selank: anti-anxiety effect in patients

    In 62 patients with generalized anxiety disorder and neurasthenia, Selank showed an anti-anxiety effect similar to medazepam, with additional anti-fatigue effects.5

    62patients in the comparison with medazepam
  4. 4

    Where they overlap

    In vitro, both have been shown to inhibit the human serum enzymes that break down enkephalins (IC50 10 µM for Semax, 20 µM for Selank). In 52 healthy volunteers, each one given separately was associated with changes in amygdala connectivity on functional MRI.1,6

    52healthy volunteers in the functional MRI study
  5. 5

    The evidence is for each component

    The studies cited tested each peptide on its own; none tested the blend in one vial. In rats with a Parkinson's model, Selank was associated with less anxiety and neither peptide changed motor activity. The evidence is mostly preclinical and from Russian groups.2,6,3,5

References
  1. Kost NV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180-3. PMID 11443939
  2. Slominsky PA, et al. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Dokl Biol Sci. 2017;474(1):106-109. PMID 28702721
  3. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID 16996037
  4. Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3 Vyp 2):61-68. PMID 29798983
  5. Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID 18454096
  6. Panikratova YR, et al. Functional connectomic approach to studying Selank and Semax effects. Dokl Biol Sci. 2020;490(1):9-11. PMID 32342318

Components per vial

Reference amounts of the formulation. The physicochemical data correspond to each individual peptide.

Semax

5 mg
M1E2H3F4P5G6P7
Molecular formula
C37H51N9O10S
Molecular weight
813.9 g/mol
CAS number
80714-61-0
PubChem CID
9811102
Length
7 aa

Selank

5 mg
T1K2P3R4P5G6P7
Molecular formula
C33H57N11O9
Molecular weight
751.9 g/mol
CAS number
129954-34-3
PubChem CID
11765600
Length
7 aa

Five findings from studies

Summary of results reported in the scientific literature. Each finding describes what was observed in the cited study, in its specific population and conditions; it does not constitute a therapeutic indication.

  1. Preclinical

    Semax: in rats it has shown an increase in BDNF levels and in TrkB activation in the hippocampus.

    Dolotov OV et al. Brain Res. 2006;1117:54-60 · PMID 16996037
  2. Clinical study

    Semax: in patients with ischemic stroke it has been associated with better functional recovery.

    Gusev EI et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118:61-68 · PMID 29798983
  3. Clinical study

    Selank: in patients with generalized anxiety disorder and neurasthenia it has shown an anxiolytic effect similar to that of medazepam.

    Zozulia AA et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108:38-48 · PMID 18454096
  4. Preclinical

    Selank: in rats subjected to chronic stress it has reduced anxiety indicators and has potentiated the anxiolytic effect of diazepam.

    Kasian A et al. Behav Neurol. 2017;2017:5091027 · PMID 28280289
  5. In vitro

    Selank: in in vitro studies it has shown inhibition of enzymes that degrade enkephalins.

    Kost NV et al. Bioorg Khim. 2001;27:180-183 · PMID 11443939

More in Cognitive and Neurological Health

NAD+DSIPDSIP / Pinealon SpraySelank